Contraceptive Management in Patients with Prior Stroke

Contraindications to Estrogen‑Containing Contraceptives

Combined hormonal contraceptives that contain estrogen are formally contraindicated in women with a personal history of stroke or any arterial thrombotic event, regardless of formulation (oral pills, transdermal patches, vaginal rings). 3, 4
Even low‑dose estrogen preparations (≤ 20 µg ethinyl estradiol) increase the risk of recurrent stroke. 2, 5
Estrogen raises thrombogenic potential by altering clotting factor levels and increasing sex‑hormone‑binding globulin (SHBG). 6

Copper intrauterine device (IUD) – preferred first‑line method: > 99 % typical‑use effectiveness, provides 5–10 years of reversible contraception, and does not increase stroke risk. 3, 2, 5, 6, 7
Barrier methods (condoms) – safe (no added stroke risk) but have lower typical‑use effectiveness (< 87 %). 2, 5, 1
Surgical sterilization – > 99 % effective, no impact on stroke risk. 2, 5

Levonorgestrel IUD (Mirena) – > 99 % effectiveness, no increase in stroke risk, especially suitable for patients with complex cardiovascular disease, and reduces menstrual blood loss by 40–50 %. 7, 2, 5, 6, 8
Progestin implant (etonogestrel/Nexplanon) – > 99 % effectiveness, no stroke risk increase, provides 3 years of contraception. 2, 5, 6, 8
Progestin injection (depot medroxyprogesterone acetate) – 93–97 % effectiveness, no stroke risk increase, contraindicated in patients with heart failure because of fluid‑retention risk. 2, 5, 7, 8
Progestin‑only pills – < 90 % effectiveness (lowest among hormonal options), no stroke risk increase, require strict daily adherence. 2, 5, 6, 8

Pregnancy‑associated stroke risk is approximately 30 per 100 000 pregnancies; therefore, effective contraception is essential. 2, 5
In patients with highly complex cardiovascular disease (e.g., pulmonary hypertension), levonorgestrel IUD insertion should be performed in a hospital setting due to a ~5 % risk of vasovagal reaction. 7

The 2024 American Heart Association/American Stroke Association guidelines give a Class 2a recommendation (Level C‑LD) supporting the use of progestin‑only or non‑hormonal contraception in patients with stroke risk factors. 1, 2, 8
The French Society of Endocrinology guidelines (2012) concur, stating a formal contraindication of estrogen‑containing methods for patients with a history of arterial thrombosis. 3, 4